Taniwaki, M. et al. 2018. ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING. Mediterranean Journal of Hematology and Infectious Diseases. 10, 1 (Feb. 2018), e2018014. DOI:https://doi.org/10.4084/mjhid.2018.014.